Condition: Urothelial Carcinoma · Sponsor: Matteo Santoni
The ARON-2 study retrospectively analyze patients treated with pembrolizumab as first-line therapy in patients platinum-unfit or as second-line therapy in patients progressed after previous platinum-based chemotherapy. The amendment has been designed to also analyze patients treated with enfortumab vedotin progressed to previous platinum-based chemotherapy and anti-PD-1/PD-L1 inhibitor.
This description comes directly from the study's public registry record.
Matteo Santoni, MD, PhD · +39 07332572960 · mattymo@alice.it
Giulia Sorgentoni · sorgentoni.giulia@gmail.com
Always discuss trial participation with your own doctor first.
| Ospedale di Macerata, UOC Oncologia | Province of Macerata, Macerata, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05290038